Press releases
GSK joins WIPO Re:Search open innovation platform as part of its commitment to tackling diseases of the developing world
GlaxoSmithKline (GSK) today announced it has joined WIPO Re:Search as part of its open innovation strategy to help accelerate the development of new and better treatments against neglected tropical diseases (NTDs) which affect more than a billion people in the world’s poorest countries each year.
GSK delivers strong Q3 performance with underlying sales growth of 6% and reported sales growth of 3%
- EPS 28.5p +1% before major restructuring* - Dividend +6% to 17p - 2011 share buyback expectations increased to up to £2.3 billion Full details of GSK's results for the third quarter of 2011 can be found in the Investors section of GSK.com.
First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months
Half the world’s population is at risk of malaria which is responsible for close to 800,000 deaths each year, most of whom are children under five in sub-Saharan Africa
Regulatory Update: GlaxoSmithKline receives Complete Response letter from FDA for candidate meningococcal and Hib combination vaccine
GlaxoSmithKline [NYSE:GSK] announced today that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for the candidate meningococcal and Hib combination vaccine, MenHibrix® (Hib-MenCY-TT). The proposed indication for this combination vaccine is active immunization of infants and toddlers 6 weeks through 15 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib).
Lucozade to help drive Vodafone McLaren Mercedes performance
Ahead of this weekend’s Singapore Grand Prix, Lucozade – the UK’s leading sports and energy drink – today announces an innovative performance partnership with the Vodafone McLaren Mercedes Formula 1 team.
GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership
GlaxoSmithKline (GSK) today announced that it has formed a long term strategic partnership with McLaren Group. The partnership, which will run initially until 2016, brings together two UK companies focused on innovation and high-tech research.
GlaxoSmithKline (GSK) commits $1 million in cervical cancer vaccine to new cooperative effort aimed at reducing deaths from women's cancers
GlaxoSmithKline (GSK) today announced that it has committed $1 million in Cervarix® cervical cancer vaccine to the Pink Ribbon Red Ribbon partnership over the next five years. GSK has also pledged $50,000 to support the program operations. As a result of this donation, more than 10,000 girls and women will have access to vaccination
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
GlaxoSmithKline (GSK) and Amicus Therapeutics today announced the first patient has commenced dosing in a Phase III global registration study (Study 012) to compare the safety and efficacy of Amigal™ (migalastat HCl) and enzyme replacement therapy (ERT) for the treatment of Fabry disease. The randomised, open-label, 18-month study will provide longer-term clinical data comparing migalastat HCl to ERT in patients with Fabry disease, a rare inherited lysosomal storage disorder.
GSK gives update on agreement with World Health Organization to support de-worming of school age children in endemic countries
First African countries, Togo and Rwanda, receive albendazole donations to scale-up school based de-worming programmes for children at risk of intestinal worms. Donations to go beyond Africa to include endemic countries in Asia Pacific and Latin America.
Lapatinib clinical trial update
A planned interim review of early data from ALTTO a Phase III, four arm study of adjuvant lapatinib (Tykerb/Tyverb®), trastuzumab, their sequence and their combination in patients with HER2 positive early stage breast cancer, has resulted in a change to the ongoing study. The independent data monitoring committee that carried out the review has recommended that three of the trial arms continue without modification. However, the committee has indicated that the lapatinib alone arm is unlikely to meet the pre-specified criteria to demonstrate non-inferiority to trastuzumab alone with respect to disease-free survival. Consequent to this finding, patients assigned to the lapatinib alone arm of the trial will discontinue lapatinib and discuss treatment options with their study physician. This study is fully recruited and the remaining three arms of the trial will continue as planned. Use of lapatinib in an adjuvant setting is not approved anywhere in the world.
